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The text of the paragraph entitled “An ounce of prevention” should appear as follows. The journal regrets the error.
Cellulitis of the lower extremities is associated with signiﬁcant morbidity and health care costs. Importantly, a considerable
number of patients (estimates of 16–30%) who had a ﬁrst episode of erysipelas or uncomplicated cellulitis experience infection
recurrence. In an attempt to determine whether prophylactic antibiotic use is effective in preventing recurrent cellulitis, Oh and
colleagues performed a systematic review and meta-analysis of studies predating 2012. Five studies comprising 535 participants
were culled from databases. Results from two high-quality (PATCH) studies and three lower-quality studies indicated that
prophylactic antibiotics were beneﬁcial for preventing cellulitis (RR of 0.46, 95% CI 0.26–0.79). Although the small number of
included studies was heterogeneous, these ﬁndings support antibiotic prophylaxis against recurrent cellulitis because these
antibiotics were generally well tolerated. (J Infect 69:26–34, 2014) Selected by H. Williams.
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An incomplete grant number was provided for this publication. This work was supported by the UT MD Anderson Cancer
Center SPORE in Melanoma (P50 CA093459). The authors regret the error.
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It was brought to the authors’ attention that the description of a sensitive assay to measure serum levels of IL17 in blood was not
clearly explained in the text. This sensitive assay is run only for this marker, and in the text the authors fail to state this. These
updates pertain to three sections of the text, as shown below (updates in bold). The authors regret the error.
RESULTS
The transcriptome of “moderate-to-severe” psoriasis plaques contains 4,175 differentially expressed transcripts
Using gene array, we did not detect increased expression of many T-cell-produced cytokines, e.g., IFN-γ, IL-17, or IL-22, which
consistently have been increased in psoriasis plaques, when measured by real-time reverse transcriptase PCR (RT-PCR) methods
(Suárez Fariñas et al., 2010). However by using a more sensitive technique, single molecule counting, we were able to
quantify IL-17, at levels seven times higher in psoriatic patients than in normal controls, P-valueo0.001 (Supplementary
Figure S2 online). Hence, we also measured a set of disease-related cytokine mRNAs by RT-PCR in lesional and non-lesional
tissues from this group of patients (Supplementary Table S3 online). As expected, we detected much greater expression of
mRNAs encoding IL-23 (p40 and p19 subunits), IFN-γ, IL-17, and IL-22 in lesional versus non-lesional biopsies, with expression
in psoriasis lesions ranging from 3.6-fold to 120-fold (P-values ranging from 10− 11 to 10− 29) when measured by RT-PCR, but
generallyo2-fold on gene arrays. Hence, despite a large dynamic range to measure gene expression (16 logs), microarrays are
unreliable for detecting quantitative differences in expression of these primary cytokine mRNAs generally found in low (~2 log
values) levels (Suárez Fariñas et al., 2010).
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DISCUSSION
Given that psoriasis is increasingly recognized to be associated with comorbid conditions of obesity, diabetes, metabolic
dysregulation, and cardiovascular diseases that may be related to inﬂammation in skin (Davidovici et al., 2010), it is of interest
that associated functional pathways were also identiﬁed through IPA, including metabolic disease and cardiovascular disease
(Supplementary Figure S1b online), leading to two potential mechanisms for increased association between psoriasis and
metabolic and cardiovascular comorbidities.First, a product made in psoriatic plaques could produce diffusible hormone-like
proteins that inﬂuence the biology of distant cells/tissues (e.g., renin, vascular endothelial growth factor, and monocyte
chemoattractant 9 protein-1 (CCL2); Table 4) and IL-17 A (Supplementary Figure S2 online).
MATERIALS AND METHODS
Serum protein proﬁling
A 92-protein vendor-deﬁned multiplex Luminex-based panel (Human Map 1.6 plus IL-17 and IL-23; Rules Based Medicine, Austin, TX) was
used to proﬁle differential serum protein expression from healthy volunteers (n= 162) and patients with psoriasis (n= 149). The complete list of
analytes in the Human Map 1.6 can be found at http://rulesbasedmedicine.com/products-services/humanmap-services/human-discoverymap.
A more sensitive immunoassay, an IL-17A single-plex assay (Singulex, CA) was used to quantify IL-17A in serum from healthy
and psoriatic subjects (n= 10 in each group).
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